|
|
| Author |
Message |
Sharon Hope
medicine forum Guru
Joined: 30 Apr 2005
Posts: 752
|
 Posted: Wed Jun 21, 2006 4:16 am Post subject:
Atorvastatin associated liver disease
|
|
|
Atorvastatin associated liver disease
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16777499&query_hl=5&itool=pubmed_DocSum
Dig Liver Dis. 2006 Jun 12; [Epub ahead of print]
Atorvastatin associated liver disease.
Clarke AT, Mills PR.
Gastroenterology Unit, Gartnavel General Hospital, Glasgow, UK.
Atorvastatin, a HMG-CoA reductase inhibitor, is widely used in the treatment
of dyslipidaemia. A transient rise in serum transaminases occurs in up to 3%
of patients using atorvastatin but this is usually self-limiting and
inconsequential. Recent literature has indicated some potential for more
serious but rare idiosyncratic reactions related to this drug. Seven
patients with significant liver dysfunction from one centre during 2002-2005
are reported, with one death, that raises some concern over the safety of
atorvastatin. A total of seven other patients are reported in the
literature. The 14 patients were usually over 60 years, had a female:male
ratio of 2:1 and showed a mixed cholestatic/hepatocellular reaction. The
mean interval to onset of reaction was approximately 9 weeks and the liver
often took several months to recover. Three deaths occurred. Adverse drug
reaction reports from the UK Committee on Safety of Medicines reveal that
four deaths due to hepatobiliary disease (0.5 deaths per annum) have been
reported in association with atorvastatin treatment over 8 years.
Simvastatin has had no hepatobiliary-related fatalities reported over 15
years. While acute hepatotoxicity with atorvastatin remains uncommon, any
persistent abnormality in liver function should be treated with caution.
PMID: 16777499 [PubMed - as supplied by publisher] |
|
| Back to top |
|
 |
Recycle Ben
medicine forum beginner
Joined: 21 Jun 2006
Posts: 4
|
| Posted: Wed Jun 21, 2006 4:24 pm Post subject:
Re: Atorvastatin associated liver disease
|
|
|
I have been walking carrying a 5 pound weight in each hand. I walk about 2
miles per day. I have a small blocked artery going to my heart and take
isosorbide for the pain (among other pills for BP and cholesterol).
Occasionally I get a some pain in the chest while walking with the weights,
normally there is very little or none. Does this sound safe to do and will
this curtail more blockage of arteries (assuming I eat OK most of the time)?
Thanks.
"Sharon Hope" <shope@anet.net> wrote in message
news:z8SdnQWVv5OqVQXZnZ2dnUVZ_r2dnZ2d@comcast.com...
| Quote: | Atorvastatin associated liver disease
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16777499&query_hl=5&itool=pubmed_DocSum
Dig Liver Dis. 2006 Jun 12; [Epub ahead of print]
Atorvastatin associated liver disease.
Clarke AT, Mills PR.
Gastroenterology Unit, Gartnavel General Hospital, Glasgow, UK.
Atorvastatin, a HMG-CoA reductase inhibitor, is widely used in the
treatment of dyslipidaemia. A transient rise in serum transaminases occurs
in up to 3% of patients using atorvastatin but this is usually
self-limiting and inconsequential. Recent literature has indicated some
potential for more serious but rare idiosyncratic reactions related to
this drug. Seven patients with significant liver dysfunction from one
centre during 2002-2005 are reported, with one death, that raises some
concern over the safety of atorvastatin. A total of seven other patients
are reported in the literature. The 14 patients were usually over 60
years, had a female:male ratio of 2:1 and showed a mixed
cholestatic/hepatocellular reaction. The mean interval to onset of
reaction was approximately 9 weeks and the liver often took several months
to recover. Three deaths occurred. Adverse drug reaction reports from the
UK Committee on Safety of Medicines reveal that four deaths due to
hepatobiliary disease (0.5 deaths per annum) have been reported in
association with atorvastatin treatment over 8 years. Simvastatin has had
no hepatobiliary-related fatalities reported over 15 years. While acute
hepatotoxicity with atorvastatin remains uncommon, any persistent
abnormality in liver function should be treated with caution.
PMID: 16777499 [PubMed - as supplied by publisher]
|
|
|
| Back to top |
|
|
Recycle Ben
medicine forum beginner
Joined: 21 Jun 2006
Posts: 4
|
| Posted: Wed Jun 21, 2006 4:26 pm Post subject:
Re: Atorvastatin associated liver disease
|
|
|
Ignore this post. I replied when I was wanting to start a new thread.
"Recycle Ben" <fgh@qwez.com> wrote in message
news:Ioemg.8969$lf4.4758@newsread1.news.pas.earthlink.net...
| Quote: | I have been walking carrying a 5 pound weight in each hand. I walk about 2
miles per day. I have a small blocked artery going to my heart and take
isosorbide for the pain (among other pills for BP and cholesterol).
Occasionally I get a some pain in the chest while walking with the weights,
normally there is very little or none. Does this sound safe to do and will
this curtail more blockage of arteries (assuming I eat OK most of the
time)? Thanks.
"Sharon Hope" <shope@anet.net> wrote in message
news:z8SdnQWVv5OqVQXZnZ2dnUVZ_r2dnZ2d@comcast.com...
Atorvastatin associated liver disease
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16777499&query_hl=5&itool=pubmed_DocSum
Dig Liver Dis. 2006 Jun 12; [Epub ahead of print]
Atorvastatin associated liver disease.
Clarke AT, Mills PR.
Gastroenterology Unit, Gartnavel General Hospital, Glasgow, UK.
Atorvastatin, a HMG-CoA reductase inhibitor, is widely used in the
treatment of dyslipidaemia. A transient rise in serum transaminases
occurs in up to 3% of patients using atorvastatin but this is usually
self-limiting and inconsequential. Recent literature has indicated some
potential for more serious but rare idiosyncratic reactions related to
this drug. Seven patients with significant liver dysfunction from one
centre during 2002-2005 are reported, with one death, that raises some
concern over the safety of atorvastatin. A total of seven other patients
are reported in the literature. The 14 patients were usually over 60
years, had a female:male ratio of 2:1 and showed a mixed
cholestatic/hepatocellular reaction. The mean interval to onset of
reaction was approximately 9 weeks and the liver often took several
months to recover. Three deaths occurred. Adverse drug reaction reports
from the UK Committee on Safety of Medicines reveal that four deaths due
to hepatobiliary disease (0.5 deaths per annum) have been reported in
association with atorvastatin treatment over 8 years. Simvastatin has had
no hepatobiliary-related fatalities reported over 15 years. While acute
hepatotoxicity with atorvastatin remains uncommon, any persistent
abnormality in liver function should be treated with caution.
PMID: 16777499 [PubMed - as supplied by publisher]
|
|
|
| Back to top |
|
|
Google
|
|
| Back to top |
|
|
|
|
The time now is Fri Jan 09, 2009 9:29 pm | All times are GMT
|
|
Remortgages | Tile | Web Advertising | Guitar Lessons | Credit Cards
|
|
Copyright © 2004-2005 DeniX Solutions SRL
|
|
Other DeniX Solutions sites:
electronics forum,
Science forum
Unix/Linux blog
Unix/Linux documentation
Unix/Linux forums
|
Powered by phpBB © 2001, 2005 phpBB Group
|
|
FAQ
Search
Memberlist
Usergroups
Register
Profile
Log in to check your private messages
Log in
Forum index
»
Medicine forums
»
cardiology
